MedElevator
Войти в исследования Respiratory investigation · 2026
Bridging therapy with airway stent placement followed by immune checkpoint inhibitors in patients with lung cancer and malignant airway disorders: A retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takigawa Yuki, Sato Ken, Kudo Kenichiro, Goda Mayu, Shiraha Keisuke, Matsumoto Shoichiro, Ichikawa Takeru, Inoue Tomoyoshi, Matsuoka Suzuka, Fujiwara Miho, Taoka Masataka, Nishimura Jun, Watanabe Hiromi, Uka Mayu, Minami Daisuke, Taniguchi Akihiko, Ochi Nobuaki, Shoda Hiroyasu, Ishikawa Nobuhisa, Nogami Satoshi, Fujiwara Keiichi, Shibayama Takuo
Аннотация
BACKGROUND: Airway stent placement is used to manage malignant airway obstruction, but often these patients cannot receive immune checkpoint inhibitors (ICIs) because of poor performance status (PS). We evaluated whether stenting could enable ICI therapy and improve outcomes.
METHODS: We retrospectively reviewed patients with lung cancer who received anticancer therapy after airway stent placement from January 2016 to July 2025. Outcomes included 1-year overall survival (OS), median survival time (MST), ECOG PS changes, complications, immune-related adverse events, and stent removal.
RESULTS: Eighteen patients were included (16 non-small cell lung cancer; 2 small cell lung cancer). Median age was 71 years, and 60% had poor PS. MST was 282 days (95% CI, 120-546). MST was longer in stage III than stage IV disease (502 vs 200 days; p = 0.03) and in patients with PS 1 versus 2 after stenting (398 vs 78.5 days; p = 0.007). ECOG PS improved in 13 patients, and oxygen was discontinued in 10. Immune-related adverse events occurred in 7 patients and stent-related complications in 9; stent removal was performed in 8 cases (41%). MST was longer with ICI-containing therapy than with chemotherapy and/or radiotherapy (282 vs 139 days; p = 0.002). Stent removal was more frequent in the ICI group (44.4% vs 13.0%; p = 0.03).
CONCLUSIONS: Airway stenting can improve PS, relieve obstruction, and permit safe ICI therapy. Subsequent ICI use may extend survival and increase stent removal rates, supporting stenting as a bridging approach in oncologic airway emergencies.
METHODS: We retrospectively reviewed patients with lung cancer who received anticancer therapy after airway stent placement from January 2016 to July 2025. Outcomes included 1-year overall survival (OS), median survival time (MST), ECOG PS changes, complications, immune-related adverse events, and stent removal.
RESULTS: Eighteen patients were included (16 non-small cell lung cancer; 2 small cell lung cancer). Median age was 71 years, and 60% had poor PS. MST was 282 days (95% CI, 120-546). MST was longer in stage III than stage IV disease (502 vs 200 days; p = 0.03) and in patients with PS 1 versus 2 after stenting (398 vs 78.5 days; p = 0.007). ECOG PS improved in 13 patients, and oxygen was discontinued in 10. Immune-related adverse events occurred in 7 patients and stent-related complications in 9; stent removal was performed in 8 cases (41%). MST was longer with ICI-containing therapy than with chemotherapy and/or radiotherapy (282 vs 139 days; p = 0.002). Stent removal was more frequent in the ICI group (44.4% vs 13.0%; p = 0.03).
CONCLUSIONS: Airway stenting can improve PS, relieve obstruction, and permit safe ICI therapy. Subsequent ICI use may extend survival and increase stent removal rates, supporting stenting as a bridging approach in oncologic airway emergencies.